Cargando…
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8(+)T cells and promoting fatty acid metabolism
BACKGROUND: The phosphatidylinositol 3-kinase (PI3K) is frequently hyperactivated in cancer and plays important roles in both malignant and immune cells. The effect of PI3Kα inhibitors on the tumor microenvironment (TME) remains largely unknown. Here, we investigated the modulation of the TME by a c...
Autores principales: | Sun, Pu, Zhang, Xi, Wang, Rong-Jing, Ma, Qing-Yang, Xu, Lan, Wang, Yi, Liao, Hui-Ping, Wang, Hai-Long, Hu, Lan-Dian, Kong, Xiangyin, Ding, Jian, Meng, Ling-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354295/ https://www.ncbi.nlm.nih.gov/pubmed/34373258 http://dx.doi.org/10.1136/jitc-2021-003093 |
Ejemplares similares
-
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
por: Wang, Yu-xiang, et al.
Publicado: (2021) -
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
por: Wei, Xiao-Li, et al.
Publicado: (2022) -
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020) -
Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021) -
ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
por: Jin, Won Jong, et al.
Publicado: (2023)